Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis
Allergologie select · 01.01.2021 · 5 (01) · 128-132
DOI: 10.5414/alx02196e ↗Kurz gefasst
Fallbericht in der Zeitschrift Allergologie select, erschienen am 01.01.2021. Verfasst von Askin Gülsen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Luebeck. Die Arbeit wurde bisher 30-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Luebeck.
- Department of Dermatology and Allergology, Klinikum der Ludwig-Maximilians-Universität, Munich, and.
- Division of Clinical and Molecular Allergology, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany.
Zitieren
APA
Gülsen, A., Ruëff, F., & Jappe, U. (2021). Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis. Allergologie select, 5(01), 128-132. https://doi.org/10.5414/alx02196e
Vancouver
Gülsen A, Ruëff F, Jappe U. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis. Allergologie select. 2021;5(01):128-132. doi:10.5414/alx02196e
BibTeX
@article{Glsen2021,
author = {Gülsen, Askin and Ruëff, Franziska and Jappe, Uta},
title = {Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis},
journal = {Allergologie select},
year = {2021},
volume = {5},
number = {01},
pages = {128--132},
doi = {10.5414/alx02196e}
}
EUVIMED